Business Description
Harvard Apparatus Regenerative Technology Inc
NAICS : 311999
SIC : 5199
ISIN : US09074M2026
Total Employee Number:
8Compare
Compare
Traded in other countries / regions
HRGN.USA IPO Date
2013-10-21Description
Harvard Apparatus Regenerative Technology is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastrointestinal system and other organs that result from cancer, trauma, or birth defects. Its technology is based on a proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs. The Company has two operating and reportable segments: Regenerative Biotech, focused on the development of regenerative medicine treatments with operations currently in the United States, and Consumer Health Products relating to consumer health products with operations currently in Asia.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.54 | |||||
Equity-to-Asset | -0.82 | |||||
Debt-to-Equity | -0.47 | |||||
Debt-to-EBITDA | -0.1 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -100.13 | |||||
Beneish M-Score | -10.33 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 8.2 | |||||
3-Year EPS without NRI Growth Rate | 8.6 | |||||
3-Year FCF Growth Rate | 19.8 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 92.6 | |||||
9-Day RSI | 92.96 | |||||
14-Day RSI | 87.34 | |||||
3-1 Month Momentum % | -19.23 | |||||
6-1 Month Momentum % | -41.67 | |||||
12-1 Month Momentum % | -40.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.26 | |||||
Quick Ratio | 0.26 | |||||
Cash Ratio | 0.12 | |||||
Days Inventory | 10.29 | |||||
Days Sales Outstanding | 3.64 | |||||
Days Payable | 170.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13 | |||||
Shareholder Yield % | -0.09 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 7.54 | |||||
Operating Margin % | -683.3 | |||||
Net Margin % | -680.55 | |||||
EBITDA Margin % | -668.23 | |||||
FCF Margin % | -370.16 | |||||
OCF Margin % | -370.16 | |||||
ROE % | -1602.64 | |||||
ROA % | -308.17 | |||||
ROIC % | -469.03 | |||||
3-Year ROIIC % | -257.43 | |||||
ROC (Joel Greenblatt) % | -3335 | |||||
ROCE % | -1329.21 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 27.72 | |||||
EV-to-EBIT | -4.21 | |||||
EV-to-EBITDA | -4.28 | |||||
EV-to-Revenue | 28.59 | |||||
EV-to-FCF | -7.72 | |||||
Earnings Yield (Greenblatt) % | -23.75 | |||||
FCF Yield % | -13.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:HRGN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Harvard Apparatus Regenerative Technology Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.982 | ||
| EPS (TTM) ($) | -0.39 | ||
| Beta | 0.1045 | ||
| 3-Year Sharpe Ratio | -0.3 | ||
| 3-Year Sortino Ratio | -0.51 | ||
| Volatility % | 61.55 | ||
| 14-Day RSI | 87.34 | ||
| 14-Day ATR ($) | 0.026987 | ||
| 20-Day SMA ($) | 1.31355 | ||
| 12-1 Month Momentum % | -40.68 | ||
| 52-Week Range ($) | 0.96 - 2.22 | ||
| Shares Outstanding (Mil) | 17.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Harvard Apparatus Regenerative Technology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Harvard Apparatus Regenerative Technology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 69 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | 1.00 (+0.00%) | ||
| General meeting for 2025 | 2026-06-18 09:30 | 1.07 (-16.41%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 1.50 (+0.00%) | ||
| Annual report for 2025 | 2026-03-19 | 1.68 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-07 | 1.93 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-11 | 1.43 (+0.00%) | ||
| General meeting for 2024 | 2025-06-20 09:30 | 1.45 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 1.80 (-2.44%) | ||
| Annual report for 2024 | 2025-03-31 | 1.93 (-5.39%) |
Show
Entries
Harvard Apparatus Regenerative Technology Inc Frequently Asked Questions
What is Harvard Apparatus Regenerative Technology Inc(HRGN)'s stock price today?
The current price of HRGN is $1.58. The 52 week high of HRGN is $2.22 and 52 week low is $0.96.
When is next earnings date of Harvard Apparatus Regenerative Technology Inc(HRGN)?
The next earnings date of Harvard Apparatus Regenerative Technology Inc(HRGN) is 2026-11-06 Est..
Does Harvard Apparatus Regenerative Technology Inc(HRGN) pay dividends? If so, how much?
Harvard Apparatus Regenerative Technology Inc(HRGN) does not pay dividend.
Press Release
Articles on Harvard Apparatus Regenerative Technology Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers